Advertisement
News
Advertisement

Millennium hits high note with co-developed lymphoma drug

Mon, 09/27/2010 - 10:34am
Mass High Tech: The Journal of New England Technology

A Hodgkin lymphoma treatment, developed jointly by Cambridge-based Millennium: The Takeda Oncology Company and Washington state’s Seattle Genetics Inc., returned positive results from a pivotal trial.

The trial of 102 patients tested brentuximab vedotin (SGN-35), a treatment intended for Hodkin lymphoma and anaplastic large cell lymphoma that received orphan drug designation from the FDA and European Medicines Agency.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading